Rekvina Labs Ltd
Rekvina Laboratories is engaged in manufacturing injections, liquids, ointments, tablets and capsules.
- Market Cap ₹ 2.71 Cr.
- Current Price ₹ 4.50
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 0.00
- Dividend Yield 0.00 %
- ROCE 0.00 %
- ROE 0.00 %
- Face Value ₹ 5.00
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -75.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.08 | 0.08 | 0.08 | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | 0.00 | 0.00 | |
0.01 | 0.04 | 0.06 | 0.05 | 0.03 | 0.12 | 0.05 | 0.10 | 0.15 | 0.06 | 0.04 | 0.00 | 0.01 | |
Operating Profit | -0.01 | 0.04 | 0.02 | 0.03 | 0.00 | -0.06 | -0.05 | -0.10 | -0.15 | -0.06 | -0.08 | 0.00 | -0.01 |
OPM % | 50.00% | 25.00% | 37.50% | 0.00% | -100.00% | ||||||||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | |
Interest | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Profit before tax | -0.01 | 0.02 | 0.02 | 0.03 | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.01 |
Tax % | 0.00% | 0.00% | 0.00% | 33.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
-0.01 | 0.02 | 0.02 | 0.02 | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.01 | |
EPS in Rs | -0.01 | 0.02 | 0.02 | 0.02 | 0.00 | -0.05 | -0.02 | -0.07 | 0.00 | -0.05 | -0.07 | 0.00 | -0.01 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -100% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 100% |
Stock Price CAGR | |
---|---|
10 Years: | -6% |
5 Years: | -2% |
3 Years: | 4% |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -76% |
Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
Reserves | -2.39 | -2.37 | -2.36 | -2.33 | -2.45 | -2.51 | -2.53 | -2.61 | -2.86 | -2.92 | -3.00 | -3.00 | -3.01 |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.17 | 0.21 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | |
0.00 | 0.02 | 0.08 | 0.09 | 0.09 | 0.13 | 0.14 | 0.19 | 0.13 | 0.15 | 0.18 | 0.11 | 0.20 | |
Total Liabilities | 0.62 | 0.66 | 0.73 | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.20 |
0.27 | 0.27 | 0.27 | 0.27 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
0.30 | 0.34 | 0.41 | 0.45 | 0.46 | 0.44 | 0.59 | 0.60 | 0.08 | 0.04 | -0.01 | 0.00 | 0.00 | |
Total Assets | 0.62 | 0.66 | 0.73 | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.20 |
Cash Flows
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | ||
0.00 | 0.00 | 0.01 | 0.02 | 0.07 | -0.07 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | ||
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.16 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | ||
Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.10 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 |
Ratios
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 365.00 | 730.00 | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | ||||||
Inventory Days | 0.00 | |||||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | 365.00 | 730.00 | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | ||||||
Working Capital Days | 1,277.50 | 1,368.75 | 1,460.00 | 4,136.67 | 1,520.83 | -1,642.50 | ||||||
ROCE % | -1.60% | 6.35% | 3.10% | 4.51% | 0.00% | -11.11% | -3.45% | -12.70% | 0.00% |
Documents
Announcements
- Closure of Trading Window 1 Apr
- Clarification Letter For Outcome Of The Board Meeting Pursuant To Regulation 30 &33 Of SEBI (LODR) Regulations, 2015 Dated 12.02.2024 6 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Feb - Newspaper advertisement titled statement of standalone unaudited financial results for the Quarter and Nine Months ended on 31st December, 2023
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Feb - Newspaper advertisement titled statement of standalone unaudited Financial results for the Quarter ended on June 2022
- Unaudited Quarter Results Alongwith Limited Review Report For The Quarter Ended 31St December,2023 12 Feb